First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001
Clinical trial NCT02896231 · COMPLETED
Trial details
- NCT number
- NCT02896231
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-01
- Primary completion
- 2019-10-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.